Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Interdigital Tinea Pedis Study Of VT-1161
3/12/2014 8:16:59 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company’s novel oral antifungal compound, in patients with moderate-to-severe interdigital tinea pedis (ITP), also known as athlete’s foot. This study is intended as a precursor to a Phase 2b study in patients with onychomycosis, a very common fungal infection of the nail. VT-1161 is an inhibitor of the fungal enzyme CYP51, the target of the current triazole antifungals, but is from a novel chemical class that was rationally designed by Viamet with the goal of providing a superior efficacy profile and avoiding many of the side effects that characterize these current triazole antifungal agents.
Help employers find you! Check out all the jobs and post your resume.
comments powered by